NASDAQ:REPL - Nasdaq - US76029N1063 - Common Stock - Currency: USD
13.98
-0.33 (-2.31%)
The current stock price of REPL is 13.98 USD. In the past month the price increased by 1.67%. In the past year, price increased by 69.87%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Replimune Group, Inc. is a clinical-stage biotechnology company. The company is headquartered in Woburn, Massachusetts and currently employs 331 full-time employees. The company went IPO on 2018-07-20. The Company’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. RP1 (vusolimogene oderparepvec) is its lead product candidate and is based on a proprietary strain of herpes simplex virus engineered and genetically armed with a fusogenic protein (GALV-GP R-) and GM-CSF intended to maximize tumor killing potency, the immunogenicity of tumor cell death, and the activation of a systemic anti-tumor immune response. The company is also developing additional product candidates, RP2 and RP3, to enhance anti-tumor immune responses and are intended to address additional tumor types, including traditionally less immune responsive tumor types. RP2 additionally expresses an anti-CTLA-4 antibody-like molecule, as well as GALV-GP R- and GM-CSF.
REPLIMUNE GROUP INC
500 Unicorn Park Dr
Woburn MASSACHUSETTS 01801 US
CEO: Philip Astley-Sparke
Employees: 331
Company Website: https://www.replimune.com/
Investor Relations: https://ir.replimune.com/
Phone: 17812229600
The current stock price of REPL is 13.98 USD. The price decreased by -2.31% in the last trading session.
The exchange symbol of REPLIMUNE GROUP INC is REPL and it is listed on the Nasdaq exchange.
REPL stock is listed on the Nasdaq exchange.
14 analysts have analysed REPL and the average price target is 21.29 USD. This implies a price increase of 52.31% is expected in the next year compared to the current price of 13.98. Check the REPLIMUNE GROUP INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
REPLIMUNE GROUP INC (REPL) has a market capitalization of 1.08B USD. This makes REPL a Small Cap stock.
REPLIMUNE GROUP INC (REPL) currently has 331 employees.
REPLIMUNE GROUP INC (REPL) has a support level at 13.97 and a resistance level at 14.04. Check the full technical report for a detailed analysis of REPL support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
REPL does not pay a dividend.
REPLIMUNE GROUP INC (REPL) will report earnings on 2025-05-14, after the market close.
REPLIMUNE GROUP INC (REPL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.07).
The outstanding short interest for REPLIMUNE GROUP INC (REPL) is 11.66% of its float. Check the ownership tab for more information on the REPL short interest.
ChartMill assigns a technical rating of 9 / 10 to REPL. When comparing the yearly performance of all stocks, REPL is one of the better performing stocks in the market, outperforming 90.81% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to REPL. The financial health of REPL is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months REPL reported a non-GAAP Earnings per Share(EPS) of -3.07. The EPS increased by 2.85% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -37.81% | ||
ROE | -47.32% | ||
Debt/Equity | 0.14 |
ChartMill assigns a Buy % Consensus number of 86% to REPL. The Buy consensus is the average rating of analysts ratings from 14 analysts.